Overview

Study on Sintilimab in Stage IV High Risk Neuroblastoma

Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
A phase I observational study on the safety and efficacy of treatment of recurrent stage IV high risk neuroblastoma with Nivolumab
Phase:
Early Phase 1
Details
Lead Sponsor:
Shanghai Children's Medical Center
Treatments:
Nivolumab